Browse articles from EyeWorld.org related to DMEK. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ One-year data from first-in-human drug eluting IOL
➤ Company begins two Phase 2 studies for glaucoma treatment
➤ First patient dosed in allogenic cell therapy trial
➤ Company outlines resubmission plan for reproxalap NDA
➤ Safety information for the upcoming solar eclipse
➤ Upcoming company presentations at Eyecelerator and the ASCRS Annual Meeting
➤ Complimentary access to video journal
➤ ASCRS news and events
➤ Phase 3 clinical trial for water-free dry eye cyclosporine drop
➤ Phase 2b results for drug-eluting contact lens for glaucoma
➤ Dosing continues for Phase 1/2 trial evaluating gene therapy for X-linked retinoschisis
➤ Higher dose, extended wet AMD treatment non-inferior to standard of care
➤ Study: AI detects severe retinopathy of prematurity with 100% accuracy
➤ Complimentary access to video journal
➤ ASCRS news and events
➤ Update on safety review of geographic atrophy drug
➤ IND application accepted by FDA for wet AMD gene therapy
➤ Phase 2 trial planned for investigational neuropathic corneal pain treatment
➤ Interim Phase 2 data for sustained wet AMD treatment
➤ ASCRS news and events
“Best practices are the summation of the technical aspects of medicine. They are, in effect, the perfection of the form of medicine,” said Julie Schallhorn, MD. She shared this and other thoughts on best practices and gave a preview of the articles in the Cornea section of the issue.
It’s not uncommon for cornea specialists to come across a glaucoma patient in need of an endothelial transplant, and the management of these patients has certain nuances. EyeWorld spoke with two experts for their insights on how to best manage glaucoma patients who need lamellar keratoplasty.
Is DSAEK being taught less and less to surgeons in training in favor of DMEK? Three physicians shared their thoughts on the status of these two procedures in training programs and in practice.
Cornea Editor Julie Schallhorn, MD, discusses the importance of the in-person education that physicians will find at the ASCRS Annual Meeting and previews the articles in the Cornea section of the issue.
➤ Alert: eye infections linked to artificial tear
➤ Phase 2 data from research targeting Sjogren’s treatment
➤ First patient dosed in Phase 1 study for epithelial defect treatment
➤ Study compares DMEK tissue preparation techniques
➤ Topline results from oral diabetic retinopathy treatment trial
➤ ASCRS news and events
When treating endothelial dysfunction, surgeons have several options. The current standard of care is endothelial keratoplasty, DSAEK and DMEK. One new therapy that has been getting a lot of attention is corneal endothelial cell therapy, and there has been significant progress in the last 18 months.
➤ FDA grants IND for Stargardt gene therapy
➤ Phase 2 clinical trial evaluates oral nicotinamide and pyruvate effect on visual function
➤ First ophthalmic formulation of bevacizumab moves toward FDA BLA submission
➤ Positive results for faricimab as an investigational treatment for wet AMD, DME
➤ Eye scans and AI predict risk of heart attack
➤ ASCRS news and events
